Direct Biologics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 49

Employees

  • Latest Deal Type
  • Series B

  • Investors
  • 3

Direct Biologics General Information

Description

Developer of regenerative therapies designed for developing Extracellular Vesicle products derived from adult human mesenchymal stem/stromal cells. The company's technology contains bioactive molecules with clinical therapeutic potential that are processed under controlled, specified, and validated current conditions that are compliant with the quality standards and stimulate a wide array of regulatory proteins to modulate within the normal healing cascade, enabling patients to have access to healing through advanced repairment and reconstruction of their tissue.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5301 Southwest Parkway
  • Building 1, Suite 415
  • Austin, TX 78735
  • United States
+1 (800)
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 5301 Southwest Parkway
  • Building 1, Suite 415
  • Austin, TX 78735
  • United States
+1 (800)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Direct Biologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) 01-Jun-2025 Completed Clinical Trials - Phase 3
3. Reverse Merger 15-Feb-2023 Cancelled Clinical Trials - Phase 3
2. Debt - PPP 28-Apr-2020 $434K $3.5M Completed Clinical Trials - Phase 3
1. Early Stage VC (Series A1) 01-Jun-2019 $3.5M $3.5M Completed Clinical Trials - Phase 3
To view Direct Biologics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Direct Biologics Patents

Direct Biologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260166087-A1 Compositions and methods for treating acute respiratory distress syndrome Pending 05-Nov-2024
WO-2026090438-A1 Compositions and methods for treating acute respiratory distress syndrome Pending 25-Oct-2024
WO-2026072817-A1 Treatment of idiopathic facial paralysis with extracellular vesicle composition Pending 25-Sep-2024
US-12502407-B2 Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles Active 25-Apr-2024
US-20250332200-A1 Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles Active 25-Apr-2024 A61K35/28
To view Direct Biologics’s complete patent history, request access »

Direct Biologics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Direct Biologics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
IB Investments Venture Capital Minority
Tranquillion Impact Investing Minority
Granite Oak Capital Other Minority
To view Direct Biologics’s complete investors history, request access »

Direct Biologics Acquisitions (1)

Direct Biologics’s most recent deal was a Merger/Acquisition with Paisley Laboratories. The deal was made on 16-Nov-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Paisley Laboratories 16-Nov-2018 Merger/Acquisition Drug Discovery
To view Direct Biologics’s complete acquisitions history, request access »

Direct Biologics FAQs

  • When was Direct Biologics founded?

    Direct Biologics was founded in 2017.

  • Where is Direct Biologics headquartered?

    Direct Biologics is headquartered in Austin, TX.

  • What is the size of Direct Biologics?

    Direct Biologics has 49 total employees.

  • What industry is Direct Biologics in?

    Direct Biologics’s primary industry is Drug Delivery.

  • Is Direct Biologics a private or public company?

    Direct Biologics is a Private company.

  • What is Direct Biologics’s current revenue?

    The current revenue for Direct Biologics is .

  • How much funding has Direct Biologics raised over time?

    Direct Biologics has raised $3.5M.

  • Who are Direct Biologics’s investors?

    IB Investments, Tranquillion, and Granite Oak Capital have invested in Direct Biologics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process